DNTH — Stock Film
STOCK FILMSCENE 1/11DNTH · $106
Stock Expert AI presents
DNTH
Dianthus Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Dianthus Therapeutics, Inc. A quick introduction.

On the stock market since 2018, it operates in the world of health and science. It has 92 employees. Now — the numbers.

on the stock market since 2018
92 employees
$4.4B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $81.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.

$1.5M
2021
$6.4M
2022
$2.8M
2023
$6.2M
2024
$2M
2025
In the vault right now:
$0
DEBT: $1.4M
At this pace, that money lasts about 2.5 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
37
weak

Clearly below the class average.

FINANCIAL STRENGTH
77
strong

Clearly above the class average — a step short of the very top.

VALUATION
52
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
7
very weak

Clearly below the class average.

PRICE MOMENTUM
97
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 21% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $2.0M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $404.3M in the vault; even if every debt were paid off, $402.9M would remain.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $162.3M against $2.0M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 2.5 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, DNTH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: DNTH is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film